Duke University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Duke University sits in the top decile of US sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count).
Duke University: 1,725 sponsored US clinical trials, 187 recruiting.
Duke University sponsors 1,725 registered US clinical trials on ClinicalTrials.gov, 187 of them currently recruiting, and 1,244 completed. 175 of these trials are in Phase 3-4 (later-stage) and 311 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.
Top-decile sponsor footprint
Duke University ranks in the top decile of sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,244 of 1,444 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,725 total, page 28 of 35
Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study
NCT01132846
Single Dose Partial Breast Radiotherapy
NCT00944528
Understanding of Genetic Risk Information for Type 2 Diabetes
NCT01186354
PROspective Multicenter Imaging Study for Evaluation of Chest Pain
NCT01174550
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
NCT01723709
Treatment of Palmar Plantar Erythrodysesthesia (PPE) With Topical Sildenafil
NCT01219023
"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"
NCT01121770
Community Based Obesity Prevention Among Blacks
NCT00939081
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
NCT00987415
Trial of Collaborative Depression Care Management for HIV Patients
NCT01372605
Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias
NCT01151527
Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
NCT01121757
Centers for Education on Research and Therapeutics - Heart Failure: Targeted Intervention Study
NCT00979264
Outlook: An Intervention to Improve Quality of Life in Serious Illness
NCT00939146
Uncertainty Management Intervention
NCT00938795
Mother Sibling Interactions Following Very Low Birth Weight (VLBW) Infant Homecoming
NCT01385254
Stroke Education Intervention Trial - Pilot
NCT01115660
An Open Label Study to Describe the Pharmacokinetics of Daptomycin in Infants
NCT00942149
Parent Treatment for Child Social Adjustment
NCT01765166
Moderate to Persistent Asthma in the Obese Subject
NCT01016847
Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma
NCT01216436
Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma
NCT01004874
Care Transitions for Complex Patient - Cycle 1 and Cycle 2
NCT01039324
Optimal Planning Target Volume With Stereotactic Radiosurgery
NCT01017497
Radiosurgery and Avastin for Recurrent Malignant Gliomas
NCT01017250
Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity
NCT01017263
Memantine and Postoperative Pain
NCT01032759
Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer
NCT00941915
Supplemental Nicotine Administration for Smoking Cessation in Posttraumatic Stress Disorder (PTSD)
NCT01055886
Obesity in HIV After Antiretroviral Therapy
NCT01461876
Community Based Obesity Prevention Among Black Women
NCT00938535
Rivastigmine Study in Adolescents With Down Syndrome
NCT01084135
Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF
NCT00650091
Cerebral Perfusion Pressure Using Precedex and Other Sedatives
NCT01169467
Functional Imaging of Tumor and Normal Tissue
NCT00933114
AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis
NCT00957242
Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies
NCT00921739
Clinical Decision Support for Medication Management and Adherence
NCT00979225
Intraoperative OCT Guidance of Intraocular Surgery
NCT01588041
The Effect of Depth of Anesthesia as Measured by Bispectral Index (BIS) on Emergence Agitation in Children
NCT00990769
CONNECT for Quality: A Study to Reduce Falls in Nursing Homes
NCT00636675
Teen CHAT: Improving Physician Communication With Adolescents About Healthy Weight
NCT01040975
Mechanisms and Functional Outcomes of Exercise Progression Models in the Elderly
NCT01899586
Fast Spectral Imaging Device for Tumor Margin Mapping
NCT01107080
Nonin 4 Wavelength Cerebral Oximeter Study
NCT01762722
Stress Management and Biomarkers of Risk in Cardiac Rehabilitation
NCT00981253
Enhanced Self-Efficacy Training
NCT00938769
Impact of Aggressive Versus Standard Drainage Regimen Using a Long Term Indwelling Pleural Catheter
NCT00978939
Tailored Intervention Protocol for Oral Chemotherapy Adherence
NCT00932490
The CARRA Registry
NCT01697254
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 136 |
| Phase 2 | 175 |
| Phase 3 | 41 |
| Phase 4 | 134 |
Therapeutic Areas
What is open in the Duke University pipeline
187 recruiting of 1,725 indexed (11% open); 1,244 completed (72%).
Phase mix: 175 late (III/IV) vs 311 early (I/II) (early-phase heavy).
Top condition: Obesity (15 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Duke University: open-pipeline peers nationwide
Peers matched on 1,725 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
Duke University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,725 trials (± recruiting share)
- University of California, San Francisco · 1,713 trials · 16% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- VA Office of Research and Development · 1,668 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
Sponsors near 11% open enrollment (± trial volume)
- Carnegie Mellon University · 11% recruiting · 37 trials
- CAMC Health System · 11% recruiting · 28 trials
- UConn Health · 11% recruiting · 178 trials
- Hartford Hospital · 11% recruiting · 75 trials
Related
What to do with this Duke University page
1,725 registered trials is a research-attention snapshot, not an endorsement of Duke University or any single study.
- 187 of Duke University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition Duke University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Duke University pipeline card: 1,725 registered trials from official public datasets.Report a data error.